IL-27 Counteracts Neuropathic Pain Development Through Induction of IL-10
Neuroimmune-glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain proce...
Saved in:
Published in | Frontiers in immunology Vol. 10; p. 3059 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
28.01.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Neuroimmune-glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain process. Here, we found that neuropathic pain caused by peripheral nerve injury (spared nerve injury model; SNI), was enhanced in IL-27-deficient
mice, whereas nociceptive pain is similar to that of wild-type mice. SNI induced an increase in the expression of IL-27 and its receptor subunit (
) in the sensory ganglia and spinal cord. IL-27 receptor was expressed mainly in resident macrophage, microglia, and astrocytes of the sensory ganglia and spinal cord, respectively. Finally, we identify that the antinociceptive effect of IL-27 was not observed in IL-10
mice. These results provided evidence that IL-27 is a cytokine produced after peripheral nerve injury that counteracts neuropathic pain development through induction of the antinociceptive cytokine IL-10. In summary, our study unraveled the role of IL-27 as a regulatory cytokine that counteracts the development of neuropathic pain after peripheral nerve damage. In conclusion, they indicate that immunotherapies based on IL-27 could emerge as possible therapeutic approaches for the prevention of neuropathic pain development after peripheral nerve injury. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology Edited by: Felipe Almeida Pinho Ribeiro, Harvard Medical School, United States Present address: Miriam M. Fonseca, Pain Mechanisms Laboratory, Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, United States Reviewed by: Felipe J. Nobre Lelis, Brigham and Women's Hospital and Harvard Medical School, United States; Rafael Gonzalez-Cano, Boston Children's Hospital and Harvard Medical School, United States; Larissa Staurengo-Ferrari, University of California, San Francisco, United States |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2019.03059 |